VF
IMDX

Virtu Financial’s Insight Molecular Diagnostics IMDX Stock Holding History

Virtu Financial’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-3,256
Closed -$15K – 1706
2023
Q2 		$15K Buy
+3,256
New +$16.4K ﹤0.01% 1308
2022
Q4 		– Sell
-528
Closed -$8K – 1988
2022
Q3 		$8K Sell
528
-509
-49% -$8.81K ﹤0.01% 1539
2022
Q2 		$19K Buy
+1,037
New +$23.6K ﹤0.01% 1341
2021
Q1 		– Sell
-1,852
Closed -$89K – 1898
2020
Q4 		$89K Buy
+1,852
New +$67.9K 0.01% 1091
2020
Q3 		– Sell
-1,325
Closed -$51K – 1370
2020
Q2 		$51K Buy
+1,325
New +$68.4K 0.01% 1003
2019
Q4 		$51K Buy
+1,140
New +$41.1K 0.01% 1199
2019
Q2 		– Sell
-1,444
Closed -$114K – 1734
2019
Q1 		$114K Buy
+1,444
New +$93.1K 0.01% 1112

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Virtu Financial's IMDX Position: Q3 2023 in Review

Virtu Financial sold out of Insight Molecular Diagnostics (IMDX) in Q3 2023, closing a stake of 3,256 shares — an estimated $15K sold.

Virtu Financial first reported a position in IMDX in Q1 2019 and held it in 7 quarters. The position peaked at $114K in Q1 2019. 30 funds tracked by Wall St. Rank hold IMDX as of Q3 2023.

  • Virtu Financial reported no remaining Insight Molecular Diagnostics position as of Q3 2023 after selling out during the quarter.
  • Virtu Financial sold 3,256 Insight Molecular Diagnostics shares in Q3 2023, an estimated $15K.
  • Virtu Financial first reported a position in Insight Molecular Diagnostics in Q1 2019 and held it in 7 quarters.
  • Virtu Financial's Insight Molecular Diagnostics position peaked at $114K in Q1 2019.
  • 30 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q3 2023.

Based on Virtu Financial's 13F filing for Q3 2023, filed 15 Nov 2023.